Abstract P4-11-12: Quality of life, anxiety and depression during treatment of ductal carcinoma in situ and invasive breast cancer

2016 ◽  
Author(s):  
DA Young-Afat ◽  
ML Gregorowitsch ◽  
J-P Pignol ◽  
CH van Gils ◽  
M van Vulpen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Ductal Carcinoma In Situ ◽  
Invasive Breast Cancer ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Anxiety And Depression

scholarly journals A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ

2007 ◽  
Vol 43 (3) ◽  
pp. 549-556 ◽  
Author(s):  
Y.R.B.M. van Gestel ◽  
A.C. Voogd ◽  
A.J.J.M. Vingerhoets ◽  
F. Mols ◽  
G.A.P. Nieuwenhuijzen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Risk Perception ◽  
Ductal Carcinoma In Situ ◽  
Invasive Breast Cancer ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Disease Impact

What quality-of-life issues do women with ductal carcinoma in situ (DCIS) consider important when making treatment decisions?

Breast Cancer ◽  
2017 ◽  
Vol 24 (5) ◽  
pp. 720-729 ◽  
Author(s):  
Rebecca Mercieca-Bebber ◽  
Madeleine T. King ◽  
Miriam M. Boxer ◽  
Andrew Spillane ◽  
Zoë E. Winters ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Treatment Decisions ◽  
Life Issues

scholarly journals Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer

ISRN Oncology ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Andrei Dobrescu ◽  
Monique Chang ◽  
Vatsala Kirtani ◽  
George K. Turi ◽  
Randa Hennawy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma In Situ ◽  
Invasive Breast Cancer ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Receptor Expression ◽  
Invasive Cancer ◽  
Positive Staining ◽  
Receptor Status

Background. To our knowledge, the hormone receptor status of noncontiguous ductal carcinoma in situ (DCIS) occurring concurrently in ER/PgR-negative invasive cancer has not been studied. The current study was undertaken to investigate the ER/PgR receptor status of DCIS of the breast in patients with ER/PgR-negative invasive breast cancer. Methods. We reviewed the immunohistochemical (IHC) staining for ER and PgR of 187 consecutive cases of ER/PgR-negative invasive breast cancers, collected from 1995 to 2002. To meet the criteria for the study, we evaluated ER/PgR expression of DCIS cancer outside of the invasive breast cancer. Results. A total of 37 cases of DCIS meeting the above criteria were identified. Of these, 16 cases (43.2%) showed positive staining for ER, PgR, or both. Conclusions. In our study of ER/PgR-negative invasive breast cancer we found that in 8% of cases noncontiguous ER/PR-positive DCIS was present. In light of this finding, it may be important for pathologists to evaluate the ER/PgR status of DCIS occurring in the presence of ER/PgR-negative invasive cancer, as this subgroup could be considered for chemoprevention.

Characteristics of Microinvasive Ductal Carcinoma In Situ Versus Noninvasive and Invasive Breast Cancer

2020 ◽  
Vol 254 ◽  
pp. 378-383
Author(s):  
Lauren R. Strang ◽  
James Sun ◽  
Weihong Sun ◽  
David Boulware ◽  
John V. Kiluk ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma In Situ ◽  
Invasive Breast Cancer ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma
Sign in / Sign up

Export Citation Format

Share Document